期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

可变剂量帕利哌酮缓释片对急性期精神分裂症认知功能的影响 被引量：5

Cognitive effect of flexible-dose oral paliperidone extended-release tablets in treating acute schizophrenia
原文传递
导出
摘要 目的:评估可变剂量的帕利哌酮缓释片对急性期精神分裂症认知功能的影响。方法:对58例急性期精神分裂症患者进行可变剂量的帕利哌酮缓释片治疗。在治疗前和8周末分别使用成套神经心理测验对认知功能进行评估,比较治疗前后认知功能的变化。结果:经过8周的治疗,简短视觉空间记忆测验、WAIS-Ⅲ符号搜索、定步调听觉连续加法测验和威斯康星卡片分类测验的结果均有显著变化,具有统计学意义(P<0.05);而Stroop色词测验和数字符号编码测验的变化没有统计学意义。霍普金斯词语学习测验除了假阳性数在8周末显著减少外(P<0.05),其他各项的变化无统计学意义。WMS-Ⅲ空间广度测验的顺行广度得分和总分在治疗前后无显著变化,但是逆行广度得分在8周末显著升高(P<0.05)。结论:可变剂量的帕利哌酮缓释片对急性期精神分裂症患者的大部分认知功能损害有改善作用。 Objective： To evaluate the effect of flexible-dose oral paliperidone extended-release tablets on cognitive function in the treatment of acute schizophrenia. Methods： Totally 58 inpatients with acute schizophrenia participated in the open label trial, and were treated with flexible doses of paliperidone-ER （3 -12 mg·d^-1） for 8 weeks. The complete neuropsychological tests were used to evaluate inpatients＇ cognitive function at baseline and 8th week. Then the changes of cognitive function were compared before and after treatment. Results： After 8-week treatment, there were 51 inpatients belonging to ITT. At the end of 8th week, the scores of Wiscon Brife Visuospatial Memory Tests （BVMT-R）, Symbol Search Test, Paced Auditory Seria Addition Task （PASAT） and Wisconsin Card Sorting Test （WCST） were significantly improved （P 〈0.05）. In the analysis of Hopkins Verbal Learning Test-Revised （HVLT）, the number of false positives were notably higher than baseline （P 〈 0.05 ）, but other Out-comes were no statistically significant changes. Meanwhile there were no significant difference in the anterograde spatial span and the total scores of Spatial Span Subtest of Wechsler Memory Scale-HI between baseline and follow- up end point, and the scores of retrograde spatial span were significantly higher （ P 〈 O. 05 ）. Conclusion ： Flexi- ble-dose oral paliperidone extended-release tablets can significantly improve the most domain of cognitive function impairment in patients with acute schizophrenia.
作者 陈发展 周卉 陆峥 熊祥玉 黄楠 何磊英 杨程青
机构地区 同济大学医学院 上海交通大学医学院附属精神卫生中心临床精神科 同济大学附属同济医院精神医学科
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第19期2297-2301,共5页 Chinese Journal of New Drugs
关键词 帕利哌酮缓释片 精神分裂症 急性期 认知功能 开放性研究 paliperidone-extended release tablet schizophrenia acute stage cognitive function openlable stud
分类号 R969.4 [医药卫生—药理学] R971.4 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1CONDRAY R, YAO JK. Cognition, dopamine and bioaetive lip- ids in schizophrenia[ J]. Front Biosci (Schol Ed), 2011, 3 (1): 298-330.
  • 2EMSLEY R, CHILIZA B, ASMAL L, et al. The concepts of re- mission and recovery in schizophrenia[ J ] Curr Opin Psychiatry, 2011, 24(2) :114 -121.
  • 3舒良,蔡焯基,吉中孚,江开达,司天梅,张鸿燕,梅其一,贾福军,陆峥,许秀峰,孙静,邓红,关念红,李晓白,焦志安,张克让.帕利哌酮缓释片临床用药指导意见[J].中国新药杂志,2011,20(16):1514-1521. 被引量：44
  • 4石川,于欣,吴尊友,Robert K.Heaton,JIN Hua,Thomas D.Marcotte,Joseph Sadek,Igor Grant.中国HIV+/AIDS患者神经心理学初步研究[J].中国心理卫生杂志,2005,19(5):343-346. 被引量：29
  • 5WOODWRAD ND, PURDON SE, MELTZER HY, et al. A me- ta-analysis of nenropsychological change to clozapine, olanzap- ine, quetiapine, and risperidone in schizophrenia[ J ]. lnt J Neu- ropsychopharmacol, 2005, 8 (3) : 457 - 472.
  • 6CARPENTER WT, GOLD JM. Another view of therapy for cog- nition in schizophrenia [ J ]. Biol Psychiatry, 2002, 51 ( 12 ) : 969 - 971.
  • 7张毅,陈美娟,徐斐康,沈辉,钱竹书,王佩青,陆峥.抗精神病药对精神分裂症患者认知功能的影响[J].临床精神医学杂志,2010,20(1):23-25. 被引量：28
  • 8杨绪娜,朱峰,李乐华.非典型抗精神病药对首发精神分裂症患者记忆功能的影响[J].中国临床心理学杂志,2011,19(1):59-62. 被引量：17
  • 9BELLINO S, BOZZATELLO P, RINALDI C, et al. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability[ J]. Depress Res Treat, 2011, 2011:680194.
  • 10MCGURK SR, LEE MA, JAYATHILAKE K, et al. Cognitive effects of olanzapine treatment in schizophrenia [ J ]. Med Gen Med, 2004, 6 (2) : 27.

二级参考文献57

  • 1吴仁容,李乐华.新型抗精神病药:阿立哌唑[J].国外医学（精神病学分册）,2004,31(3):177-179. 被引量：380
  • 2石川,于欣,吴尊友,Robert K.Heaton,JIN Hua,Thomas D.Marcotte,Joseph Sadek,Igor Grant.中国HIV+/AIDS患者神经心理学初步研究[J].中国心理卫生杂志,2005,19(5):343-346. 被引量：29
  • 3Bilder RM, Goldman RS, Volavkal L, et al. neurocognitive effects of clozapine,olanzapine,risperdone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder[J]. Am J Psychiatry ,2002,159 : 1018-1028.
  • 4Keefe RS, Seidman LJ, Christensen BK, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis[J]. Biol Psychitry,2006 ,59 :97-105.
  • 5Keefe RSE, Seidraan LI, Christensen BK. Comparative effect of atypical and conventional antlpsychotie drugs on neurocognition in first-episode psychosis : a randomized, double-blind trial of olanzapine versus low doses of haloperidol [ J ]. Am J Psychiatry, 2004, 161:985-995.
  • 6Volaka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in treatment of patients with chronic schizophrenia and schizoaffect disorder [ J ]. Am J Psychiatry, 2002,159:255-262.
  • 7Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment [ J ]. Am J Psychiatry ,2001,158 : 176-184.
  • 8Medalia A, Lim R. Treatment of cognitive Dysfunction in Psychiatric Disorders. Journal of Psychiatric Practice, 2004, 10(1): 17-25.
  • 9Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry, 2000, 57:549-559.
  • 10Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 1996. 153:321-330.

共引文献127

同被引文献32

  • 1Spina E, Crupi R. Safety and efficacy of paliperidone extended-re- lease in acute and maintenance treatment of schizophrenia [ J ]. J Cent Nerv Syst Dis,2011,3(3) :27-41.
  • 2Laws KR. A meta-analytic review of wisconsin card sort studies in schizophrenia:general intellectual deficit in disguise? [ J]. Cogni- tive Neuropsychiatry, 1999,4 ( 1 ) : 1-35.
  • 3Juckel G, Schaub D, Fuchs N, et al. Validation of the personal and social performance (PSP) scale in a German sample of acutely ill patients with schizopbrenia[J]. Scbizophr Res,2008,104 ( 1-3 ) : 287-293.
  • 4Si T, Zhang K, Tang J, et al. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophreni- a: an open-label, single-arm, prospective, interventional study [J].Neuropsychiatr Dis Treat ,2015,22( 11 ) :1483-1492.
  • 5Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the"right stuff"[J]. Schizophr Bull,2000,26( 1 ) :119-136.
  • 6Helldin L, Peuskens J, Vauth R, et al. Treatment response, safety, and tolerability of paliperidone extended release treatment in pa- tients recently diagnosed with schizophrenia[J].Ther Adv Psycho- pbarmacol, 2015,5 ( 4 ) : 194 -207.
  • 7Hough D, Gopal S, Vijapurka U, et 8]. Paliperidone palmitate main- tenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study [J]. Schizophr Res,2010,116(2-3) :107-117.
  • 8Stip E. Cognition, schizophrenia and the effect of antipsychoties [ J ]. Encephale,2006,32 ( 3 ) : 341-350.
  • 9Emsley R,Chiliza B,Asmal L, et al. The concepts of remission and recovery in schizophrenia[J]. Curr Opin Psychiatry,2011,24 (2) :114-121.
  • 10Meltzer HY, Sumiyosh T. Does stimulation of 5-HT (1A) recep- tors improve cognition in schizophrenia [ J ]. Behav Brain Res, 2008,195( 1 ) :98-102.

二级引证文献22

中国新药杂志
2012年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部